Tags : Ziopharm

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Tuba Khan June 1, 2020

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased […]Read More

Biotech

Ziopharm Signs an Exclusive License Agreement with NIH to Develop

Tuba Khan May 29, 2019

Shots: NIH to receive $1.5M upfront, $16.3M as clinical, regulatory & commercial milestones including $3M prior to marketing approval in the US, Europe, Japan, Australia, China & India and $0.1M at the initiation of P-I study, $12M as commercial milestone and royalties on sales of products with $0.046M as reimbursement payment for patent Ziopharm to […]Read More

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for Antibody-Drug Conjugate Candidates

Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders

Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics

Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar, ustekinumab in Russia and other CIS Countries

Boehringer Ingelheim’s Cyltezo (biosimilar, adalimumab) Receives the US FDA’s sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19

Pfizer’s Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC’s Advisory Committee Recommendation for Invasive Disease and Pneumonia

Regeneron and Sanofi’s Dupixent (dupilumab) Receive the US FDA’s Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Dicerna Reports Results of Nedosiran in PHYOX4 Study for the Treatment of Primary Hyperoxaluria Type 3

Tags : Ziopharm

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Ziopharm Signs an Exclusive License Agreement with NIH to Develop

Latest Posts

Insights+: The US FDA New Drug Approvals in September 2021

Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Pfizer’s Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC’s Advisory Committee Recommendation for Invasive Disease and Pneumonia

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for Antibody-Drug Conjugate Candidates

Tags : Ziopharm

Latest Posts

Categories

Related Topics